pocketful logo light
pocketful logo light
ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

NSE: ERIS BSE: 540596

₹1458.20

(9.13%)

Mon, 25 May 2026, 06:56 pm

mtf coin illustrationMTF 5x

ERIS Lifesciences Analysis

dividend

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (7.5x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (11x coverage).
thumbs up icon

Cons

  • Eris Lifesciences only just started paying a dividend, it is too early to tell if payments are increasing.
  • It is too early to tell whether Eris Lifesciences has stable dividend payments.
  • Eris Lifesciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Eris Lifesciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

future

thumbs up icon

Pros

  • Eris Lifesciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Eris Lifesciences's earnings are expected to exceed the low risk growth rate next year.
  • Eris Lifesciences is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
  • Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
  • Eris Lifesciences's revenue growth is expected to exceed the India market average.
thumbs up icon

Cons

  • Cash flow for Eris Lifesciences is expected to increase but not above the 50% threshold in 2 years time.
  • Eris Lifesciences's earnings are expected to grow by 11% yearly, however this is not considered high growth (20% yearly).
  • Eris Lifesciences's earnings growth is positive but not above the India market average.
  • Eris Lifesciences's net income is expected to increase but not above the 50% threshold in 2 years time.
  • A decline in Eris Lifesciences's performance (ROE) is expected over the next 3 years.
  • Eris Lifesciences's revenue is expected to increase but not above the 50% threshold in 2 years time.
  • Eris Lifesciences's revenue is expected to grow by 9.4% yearly, however this is not considered high growth (20% yearly).

health

thumbs up icon

Pros

  • Eris Lifesciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eris Lifesciences is profitable, therefore cash runway is not a concern.
  • Eris Lifesciences is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (17816.4%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 315.8x debt.
  • Eris Lifesciences's cash and other short term assets cover its long term commitments.
  • The level of debt compared to net worth has been reduced over the past 5 years (1.2% vs 0.1% today).
  • Interest payments on debt are well covered by earnings (EBIT is 147.1x coverage).
  • Eris Lifesciences's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • Low level of unsold assets.
thumbs up icon

Cons

    management

    thumbs up icon

    Pros

    • The tenure for the Eris Lifesciences board of directors is about average.
    • Amit's compensation has been consistent with company performance over the past year, both up more than 20%.
    thumbs up icon

    Cons

    • Amit's remuneration is higher than average for companies of similar size in India.
    • Eris Lifesciences individual insiders have only sold shares in the past 3 months.

    past

    thumbs up icon

    Pros

    • Eris Lifesciences's year on year earnings growth rate has been positive over the past 5 years.
    • Eris Lifesciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
    • Eris Lifesciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
    thumbs up icon

    Cons

    • Eris Lifesciences's 1-year earnings growth is less than its 5-year average (1.8% vs 16.1%)
    • Eris Lifesciences's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
    • Eris Lifesciences's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (1.8% vs 22.7%).

    value

    thumbs up icon

    Pros

    • 540596 outperformed the Market in India which returned -14.5% over the past year.
    thumbs up icon

    Cons

    • Eris Lifesciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
    • Eris Lifesciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
    • Eris Lifesciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
    • Eris Lifesciences is poor value based on expected growth next year.
    • Eris Lifesciences is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
    • Eris Lifesciences is overvalued based on earnings compared to the India market.
    • 540596 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
    • BSE:540596 is down -1.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
    • BSE:540596 is down -1.1% underperforming the market in India which returned 8% over the past month.